---
title: "VTGN: Fasedienol missed primary endpoints in Phase 3, but showed promise in severe social anxiety subgroup"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291282499.md"
description: "Fasedienol did not meet primary or secondary endpoints in the PALISADE-4 Phase 3 trial for social anxiety disorder, but a post-hoc analysis showed nominal significance in patients with very severe symptoms. Plans are underway for a new Phase 3 trial with LSAS as the primary endpoint.Original document: VistaGen Therapeutics, Inc. [VTGN] Press release — Jun. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-06-30T12:18:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291282499.md)
  - [en](https://longbridge.com/en/news/291282499.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291282499.md)
---

# VTGN: Fasedienol missed primary endpoints in Phase 3, but showed promise in severe social anxiety subgroup

Fasedienol did not meet primary or secondary endpoints in the PALISADE-4 Phase 3 trial for social anxiety disorder, but a post-hoc analysis showed nominal significance in patients with very severe symptoms. Plans are underway for a new Phase 3 trial with LSAS as the primary endpoint.

Original document: VistaGen Therapeutics, Inc. \[VTGN\] Press release — Jun. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [VTGN.US](https://longbridge.com/en/quote/VTGN.US.md)

## Related News & Research

- [VistaGen says Phase 2 repeat-dose fasedienol study in social anxiety disorder shows favorable safety, efficacy signals](https://longbridge.com/en/news/295108318.md)
- [SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) | SRXH Stock News](https://longbridge.com/en/news/294794808.md)
- [Here's How Much $1000 Invested In Global X Artificial Intelligence & Technology ETF 15 Years Ago Would Be Worth Today](https://longbridge.com/en/news/294756506.md)
- [Cybin publishes corporate presentation on development of serotonergic agonists for depression, anxiety](https://longbridge.com/en/news/294701596.md)
- [Is paying artists enough to convince them to embrace AI?](https://longbridge.com/en/news/294607299.md)